New drug duo targets hard-to-treat leukemias in early trial
NCT ID NCT07356154
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and see if the combination can help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Cancer Center (Data collection only)
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
MD Anderson Cancer Center (Data Collection Only)
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITINGRockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
University of North Carolina (Data Collection Only)
NOT_YET_RECRUITINGChapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?